Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The ongoing demand for reliable, cost-effective, and scalable diagnostic solutions during the COVID-19 pandemic emphasized the need for innovative production platforms. In this study, we present a plant-based molecular farming (PMF) strategy for the production of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein fused with an Fc region (RBDw-Fc). The RBDw-Fc antigen was transiently expressed in the Nicotiana benthamiana plant, achieving high yields and purity. Its functionality was assessed through antigen–antibody binding assays. The purified antigen was subsequently employed in the development of a rapid diagnostic blot assay capable of screening plasma EDTA samples from pre- and post-vaccinated as well as pre- and post-infected individuals, demonstrating high sensitivity and specificity. Our results show that the RBDw-Fc-based assay is effective for SARS-CoV-2 detection and offers considerable advantages in terms of production speed, scalability, and cost efficiency compared to traditional systems, such as cell-culture-based production. The assay delivers accurate results in just a few minutes, making it particularly suitable for clinical and resource-limited settings. This study highlights the versatility of PMF as a platform for producing high-quality reagents, with promising applications beyond SARS-CoV-2 diagnostics. The RBDw-Fc antigen-based method provides a model for the rapid, economical, and flexible development of screening tools for emerging infectious diseases and future pandemics.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen
- Date Crossref
- 08/05/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele pays non établi dans la noticeÉtablissement de santé
-
National Agency for New Technologies pays non établi dans la noticeOrganisme public
-
ENEA Casaccia Research Centre pays non établi dans la noticeOrganisme public
-
CEINGE Biotecnologie Avanzate Franco Salvatore (Italy) pays non établi dans la noticeEntreprise
-
Ospedale dell' Angelo pays non établi dans la noticeÉtablissement de santé
-
Università degli studi di Cassino e del Lazio Meridionale pays non établi dans la noticeUniversité ou école supérieure
-
San Raffaele Roma Open University Department for the Promotion of Human Sciences and Quality of Life pays non établi dans la noticeUniversité ou école supérieure
-
InterInstitutional Multidisciplinary Biobank (BioBIM) pays non établi dans la noticeStructure de recherche
-
Laboratory of Molecular and Cellular Neuroscience pays non établi dans la noticeStructure de recherche
-
ENEA Casaccia Research Center Division of Biotechnology pays non établi dans la noticeStructure de recherche
-
Transfusion Medicine Department of Venezia pays non établi dans la noticeInstitution
Istituti di Ricovero e Cura a Carattere Scientifico, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele et National Agency for New Technologies, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.